Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembro-Adjuvant-highRisk
NCT03480672Phase 2Completed
- Sponsor
- Leipzig University
- Start
- Aug 2018
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Leipzig University. Started Aug 2018; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03480672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03480672.